Dopaminergic substitution in Parkinson’s disease

REFERENCES

• HOROWSKI R, HOROWSKI L, VOGEL S, POE WE W, KIELHORN FW: An essay on Wilhelm von Humboldt and the shaking palsy: first comprehensive description of Parkinson's disease by a patient. Neurol (1995) 45(3 Pt 1):565–568.
   Google Scholar
• PARKINSON J: An essay of the shaking palsy Lomdon, Sherwood Neely and Jones. (1817).
   Google Scholar
• BERNHEIMER H, BIRKMAYER W, HORNYKIEWICZ 0, JELLINGER K, SEITELBERGER F: Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. Neurol Sci. (1973) 20(4):415–455.
   Google Scholar
• FOLEY P, RIEDERER P: Pathogenesis and preclinical course of Parkinson's disease. Neural. Transm. Sapp]. (1999) 56:31–74.
   PubMedGoogle Scholar
• ••This review provides a comprehensive lookon the available pathogenetic hypotheses of PD.
   Google Scholar
• STAN WOOD GD, LUCKI I, MCGONIGLE P: Differential regulation of dopamine D2 and D3 receptors by chronic drug treatments. Pharmacol Exp. Ther. (2000) 295(3):1232–1240.
   PubMedGoogle Scholar
• ••This study gives some evidence for theimpact of chronic dopaminergic stimulation on dopamine receptor modulation.
   Google Scholar
• SKIRBOLL LR, GRACE AA, BUNNEYBS: Dopamine auto- and postsynaptic receptors: Electrophysiological evidence for differential sensitivity to dopamine agonists. Science (1979) 206(4414):80–82.
   PubMedGoogle Scholar
• DOURISH CT, HERBERT EN, IVERSEN SD: Blockade of apomorphine-induced yawning in rats by the dopamine autoreceptor antagonist (+)-AJ 76. Neuropharmacol (1989) 28(12):1423–1425.
   PubMedGoogle Scholar
• KROPF W, KUSCHINSKY K: Electroencephalographic correlates of the sedative effects of dopamine agonists presumably acting on autoreceptors. Neuropharmacol (1991) 30(9):953–960.
   PubMedGoogle Scholar
• ANTONINI A, SCHWARZ J, OERTEL WH, POGARELL 0, LEENDERS KL: Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and (11 C)raclopride. Mov. Disord. (1997) 12(1):33–38.
   PubMed Web of Science ®Google Scholar
• HIRSCH EC: Nigrostriatal system plasticity in Parkinson's disease: effect of dopaminergic denervation and treatment. Ann. Neurol (2000) 47(4 Suppl. 1):S115–5120.
   Google Scholar
• •This study gives some evidence for the impact of chronic dopaminergic stimulation on dopamine receptor modulation.
   Google Scholar
• MILLER JW, SHUKITT-HALE B, VILLALOBOS-MOLINA R, NADEAU MR, SELHUB J, JOSEPH JA: Effect of L-Dopa and the catechol-O-methyltransferase inhibitor Ro 41-0960 on sulfur amino acid metabolites in rats. Clin. Neuropharmacol (1997) 20(1):55–66.
   PubMedGoogle Scholar
• HUGHES AJ, LEES AJ, STERN GM: Challenge tests to predict the dopaminergic response in untreated Parkinson's disease. Neurol (1991) 4I(11):1723–1725.
   Google Scholar
• AGID Y, AHLSKOG E, ALBANESE A et al.: Levodopa in the treatment of Parkinson's disease: a consensus meeting. Mo v. Disord. (1999) 14(6):911–913.
   PubMedGoogle Scholar
• BARBATO L, STOCCHI F, MONGE A et al.: The long-duration action of levodopa may be due to a postsynaptic effect. Clin. Neurophannacol (1997) 20(5):394–401.
   PubMedGoogle Scholar
• BERRY EM, GROWDON JH, WURTMAN JJ, CABALLERO B, WURTMAN RJ: A balanced carbohydrate: protein diet in the management of Parkinson's disease. Neurol (1991) 41(8):1295–1297.
   PubMed Web of Science ®Google Scholar
• FAHN S: Controversies in the therapy ofParkinson's disease. Adv. Neurol (1996) 69:477–486.
   PubMedGoogle Scholar
• FAHN S: Is levodopa toxic? Neurol (1996) 47(6 Suppl. 3):S184–S195.
   Google Scholar
• DURIF F: Treating and preventing levodopa-induced dyskinesias: current and future strategies. Drugs Aging (1999) 14(5):337–345.
   PubMedGoogle Scholar
• OBESO JA, OLANOW CW, NUTT JG. Levodopa motor complications in Parkinson's disease. Trends Neurosci. (2000) 23(10 Suppl.):S2–S7.
   Google Scholar
• DESSIBOURG CA, GACHOUD JP: Benefits of a new galenic form of levodopa and benserazide in the treatment of patients with Parkinson's disease. Schweiz. Run dsch. Med. Prax. (1995) 84(43):1235–1238.
   PubMedGoogle Scholar
• DJALDETTI R, INZELBERG R, GILADI N et al: Oral solution of levodopa ethylester for treatment of response fluctuations in patients with advanced Parkinson's disease. Mov. Disord. (2002) 17(2):297–302.
   PubMed Web of Science ®Google Scholar
• JENNER P. Pathophysiology and biochemistry of dyskinesia: clues for the development of non-dopaminergic treatments. ./. Neurol (2000) 247\(Suppl. 2):1143–1150.
   Google Scholar
• ••This review suggests new therapeuticapproaches on the treatment of dyskinesia.
   Google Scholar
• CHASE TN, OH JD: Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications. Ann. Neurol (2000) 1399 Expert Op/n. Pharmacother. (2002) 3(1 0) 47(4 Suppl. 1):S122–S129.
   Google Scholar
• •This review explains possible mechanisms for the onset of motor complications.
   Google Scholar
• BAAS H, BEISKE AG, GHIKA Jet al.: Catechol-O-methyltransferase inhibition with tolcapone reduces the 'wearing off' phenomenon and levodopa requirements in fluctuating parkinsonian patients. I Neurol Neurosurg. Psychiatry(1997) 63(4):421–428.
   Google Scholar
• FACTOR SA, MOLHO ES, FEUSTEL PJ, BROWN DL, EVANS SM: Long-term comparative experience with tolcapone and entacapone in advanced Parkinson's disease. Clin. Neuropharmacol (2001) 24(5):295–299.
   PubMed Web of Science ®Google Scholar
• POEWE WH, DEUSCHL G, GORDIN A, KULTALAHTI ER, LEINONEN M: Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand. (2002) 105(4):245–255.
   PubMed Web of Science ®Google Scholar
• MOLLER T, WOITALLA D, SCHULZ D, PETERS S, KUHNW, PRZUNTEK H: Tolcapone increases maximum concentration of levodopa. .1 Neural Transm. (2000) 107(1):113–119.
   Google Scholar
• GERLACH M, XIAO AY, KUHN W et al: The central catechol-O-methyltransferase inhibitor tolcapone increases striatal hydroxyl radical production in L-DOPA/ carbidopa treated rats.' Neural Transm. (2001) 108(2):189–204.
   PubMedGoogle Scholar
• MOLLER T, KUHN W, PRZUNTEK H: Therapy with central active catechol-0-methyltransferase (COMT)- inhibitors: is addition of monoamine wddase (MAO)-inhibitors necessary to slow progress of neurodegenerative disorders?' Neural Transm. Gen. Sect. (1993) 92(2-3):187–195.
   Google Scholar
• RUSS H, MOLLER T, WOITALLA D, RAHBAR A, HAHN J, KUHN W: Detection of tolcapone in the cerebrospinal fluid of parkinsonian subjects. Naunyn Schmiedebergs Arch. Pharmacol (1999) 360(6):719–720.
   PubMed Web of Science ®Google Scholar
• DUPONT E, ANDERSEN A, BOAS J et al.: Sustained-release Madopar HBS compared with standard Madopar in the long-term treatment of de novo parkinsonian patients. Acta Neurol Scand. (1996) 93(1):14–20.
   PubMedGoogle Scholar
• KOLLER WC, HUTTON JT, TOLOSA E, CAPILLDEO R: Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Carbidopa/Levodopa Study Group. Neurol (1999) 53(5):1012–1019.
   Google Scholar
• CHASE TN, OH JD, KONITSIOTIS S:Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms. Neurol (2000) 247\(Suppl. 2):I136–1142.
   Google Scholar
• VERHAGEN ML, DEL DOTTO P, LEPOOLE K, KONITSIOTIS S, FANG J, CHASE TN. Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Arch. Neurol (1999) 56 (11):1383–1386.
   PubMedGoogle Scholar
• VERHAGEN ML, DEL DOTTO P, VAN DEN MP, FANG J, MOURADIAN MM, CHASE TN: Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurol (1998) 50(5):1323–1326.
   PubMed Web of Science ®Google Scholar
• •This study shows the efficacy of NMDA antagonists for the treatment of motor complications.
   Google Scholar
• RASCOL 0: The pharmacological therapeutic management of levodopa-induced dyskinesias in patients with Parkinson's disease. " Neurol (2000) 247\(Suppl. 2):I151–1157.
   Google Scholar
• MERIMS D, ZIV I, DJALDETTI R, MELAMED E: Riluzole for levodopa-induced dyskinesias in advanced Parkinson's disease. Lancet (1999) 353(9166)1764–1765.
   Google Scholar
• SPIEKER S, LOSCHMANN PA, KLOCKGETHER T: The NMDA antagonist budipine can alleviate levodopa-induced motor fluctuations. Mov. Disord. (1999) 14(3):517–519.
   PubMed Web of Science ®Google Scholar
• BIBBIANI F, OH JD, CHASE TN: Serotonin 5-HT 1A agonist improves motor complications in rodent and primate parkinsonian models. Neurol (2001) 57(10):1829–1834.
   PubMedGoogle Scholar
• •This study shows the efficacy of sarizotan for the treatment of dyskinesia.
   Google Scholar
• AGID Y: Levodopa: is toxicity a myth? Neurol (1998) 50(4):858–863.
   PubMedGoogle Scholar
• MURER MG, DZIEWCZAPOLSKI G, MENALLED LB et at Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann. Neurol (1998) 43(5):561–575.
   PubMed Web of Science ®Google Scholar
• BEN SHLOMO Y, MARMOT MG: Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology? I Neurol Neurosurg. Psychiatry (1995) 58(3):293–299.
   Google Scholar
• GORELL JM, JOHNSON CC, RYBICKI BA: Parkinson's disease and its comorbid disorders: an analysis of Michigan mortality data, 1970 to 1990. Neurol (1994) 44(10):1865–1868.
   PubMedGoogle Scholar
• ALLAIN P, LE BOUIL A, CORDILLET E,LE QUAY L, BAGHERI H, MONTASTRUC JL: Sulfate and cysteine levels in the plasma of patients with Parkinson's disease. Neurotoxicol (1995) 16(3):527–529.
   PubMedGoogle Scholar
• KUHN W, ROEBROEK R, BLOM H, VAN OPPENRAAIJ D, MOLLER T: Hyperhomocysteinaemia in Parkinson's disease. I Neurol (1998) 245(12):811–812.
   PubMedGoogle Scholar
• KUHN W, ROEBROEK R, BLOM H et al.: Elevated plasma levels of homocysteine in Parkinson's disease. Eur: Neurol (1998) 40(4):225–227.
   PubMedGoogle Scholar
• BLANDINI F, FANCELLU R, MARTIGNONI E et al.: Plasma homocysteine and 1-dopa metabolism in patients with Parkinson's disease. Clin. Chem. (2001) 47(6):1102–1104.
   PubMedGoogle Scholar
• KUHN W, HUMMEL T, WOITALLA D, MOLLER T: Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. Neurol (2001) 56(2):281–282.
   PubMedGoogle Scholar
• MOLLER T, WOITALLA D, HAUPTMANN B, FOWLER B, KUHN W: Decrease of methionine and S-adenosylmethionine and increase of homocysteine in treated patients with Parkinson's disease. Neurosci. Lett. (2001) 308(1):54–56.
   PubMedGoogle Scholar
• •This study supports the concept of levodopa-associated homocysteine elevation.
   Google Scholar
• YASUI K, KOWA H, NAKASO K, TAKESHIMA T, NAKASHIMA K: Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. Neurol (2000) 55(3):437–440.
   PubMed Web of Science ®Google Scholar
• •This study supports the concept of levodopa associated homocysteine elevation.
   Google Scholar
• MOLLER T, WERNE B, FOWLER B, KUHN W: Nigral endothelial dysfunction, homocysteine, and Parkinson's disease. Lancet (1999) 354(9173):126–127.
   PubMedGoogle Scholar
• •This letter shows an elevation of homocysteine only in levodopa treated PD patients.
   Google Scholar
• MOLLER T, WOITALLA D, FOWLER B, KUHN W: 3-0MD and homocysteine plasma levels in parkinsonian patients.' Neural Transm. (2002) 109(2):175–179.
   PubMedGoogle Scholar
• •This study supports the concept of 1400 Expert Op/n. Pharmacother. (2002) 3(10) levodopa-associated homocysteine elevation.
   Google Scholar
• CHAMBERS JC, MCGREGOR A, JEAN- MARIE J, KOONER JS: Acute hyperhomocysteinaemia and endothelial dysfunction. Lancet (1998) 351(9095):36–37.
   PubMed Web of Science ®Google Scholar
• PERRY IJ: Homocysteine and risk of stroke. Cardiovasc. Rick (1999) 6(4):235–240.
   PubMedGoogle Scholar
• SCHLUSSEL E, PREIBISCH G, PUTTERS, ELSTNER EF: Homocysteine-induced oxidative damage: mechanisms and possible roles in neurodegenerative and atherogenic processes. Z Naturforsch (C) (1995) 50(9-10):699–707.
   PubMedGoogle Scholar
• MOLLER T: Non-dopaminergic drug treatment of Parkinson's disease. Expert. Opin. Pharmacother. (2001) 2(4):557–572.
   PubMedGoogle Scholar
• BEAL MF: Excitotoxicity and nitric oxide in Parkinson's disease pathogenesis. Ann. Neurol. (1998) 44(3 Suppl. 1):5110–5114.
   Google Scholar
• GERLACH M, BLUM-DEGEN D, LAN J, RIEDERER P: Nitric oxide in the pathogenesis of Parkinson's disease. Adv. Neurol. (1999) 80:239–245.
   PubMedGoogle Scholar
• LIPTON SA, KIM WK, CHOI YB et al.: Neurotoxicity associated with dual actions of homocysteine at the N- methyl-D-aspartate receptor. Proc. Natl. Acad. Sd. USA (1997) 94(11):5923–5928.
   PubMed Web of Science ®Google Scholar
• KANG SS, WONG PW: Genetic and nongenetic factors for moderate hyperhomocyst(e)inemia. Atherosclerosis (1996) 119(2):135–138.
   PubMed Web of Science ®Google Scholar
• SACHDEV PS, VALENZUELA M, WANG XL, LOOI JC, BRODATY H: Relationship between plasma homocysteine levels and brain atrophy in healthy elderly individuals. Neurol. (2002) 58(10):1539–1541.
   PubMedGoogle Scholar
• MALINOW MR: Homocyst(e)ine, vitamins and genetic interactions in vascular disease. Can. J. CardioL (1999) 15(Suppl. B):31B–34B.
   Google Scholar
• A randomized controlled trial comparingpramipexole with levodopa in early Parkinson's disease: design and methods of the CALM-PD Study. Parkinson Study Group. Clin. Neuropharmacol. (2000) 23(1):34–44.
   PubMedGoogle Scholar
• HELY MA, MORRIS JG, TRAFICANTE R, REID WG, O'SULLIVAN DJ, WILLIAMSON PM: The Sydney multicentre study of Parkinson's disease: progression and mortality at 10 years. Neurol. Neurosurg. Psychiatry (1999) 67(3):300–307.
   PubMed Web of Science ®Google Scholar
• PRZUNTEK H, WELZEL D, GERLACH M et al.: Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study. J. Neural Transm. Gen. Sect. (1996) 103(0699–715.
   PubMed Web of Science ®Google Scholar
• RASCOL 0, BROOKS DJ, KORCZYN AD, DE DEYN PP, CLARKE CE, LANG AE: A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl. J. Med. (2000) 342(20):1484–1491.
   Google Scholar
• RINNE UK, BRACCO F, CHOUZA C et al.: Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs (1998) 55\(Suppl. 1):23–30.
   Google Scholar
• RINNE UK: Combination therapy with lisuride and L-dopa in the early stages of Parkinson's disease decreases and delays the development of motor fluctuations. Long-term study over 10 years in comparison with L-dopa monotherapy. Nervenarzt (1999) 70\(Suppl. 1):519–525.
   Google Scholar
• MAREK K, SEIBYL J, SHOULSON I et al.: Dopamine transporter brain imaging to assess the effects of pramipexole versus levodopa on Parkinson's disease progression. "AMA (2002) 287(13):1653–1661.
   PubMedGoogle Scholar
• •This study shows less nigrostriatal presynaptic dopaminergic neuronal degeneration with pramipexole compared to levodopa.
   Google Scholar
• COLOSIMO C, MERELLO M, HUGHES AJ, SIERADZAN K, LEES AJ: Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon. J. Neurol. Neurosurg. Psychiatry(1996) 60(6):634–637.
   PubMedGoogle Scholar
• GOETZ CG, DIEDERICH NJ: Dopaminergic agonists in the treatment of Parkinson's disease. Neurol. Clin. (1992) 10(2):527–540.
   PubMed Web of Science ®Google Scholar
• HUGHES AJ, LEES AJ, STERN GM: Apomorphine in the diagnosis and treatment of parkinsonian tremor. Clin. Neuropharmacol (1990) 13(4):312–317.
   PubMedGoogle Scholar
• LEES AJ: Dopamine agonists in Parkinson's disease: a look at apomorphine. Fundam. Clin. Pharmacol. (1993) 7(3-4):121–128.
   PubMedGoogle Scholar
• MERELLO M, PIKIELNY R, CAMMAROTA A, LEIGUARDA R: Comparison of subcutaneous apomorphine versus dispersible madopar latency and effect duration in Parkinson's disease patients: a double-blind single-dose study. Clin. Neuropharmacol. (1997) 20(2):165–167.
   PubMed Web of Science ®Google Scholar
• MONTASTRUC JL, RASCOL 0, SENARD JM: Sublingual apomorphine in Parkinson's disease: a clinical and pharmacokinetic study. Clin. Neuropharmacol. (1991) 14(5):432–437.
   PubMed Web of Science ®Google Scholar
• CALNE DB: Early idiopathic parkinsonism: initiation and optimization of treatment. Clin. Neuropharmacol. (1994) 17\(Suppl. 2):514–518.
   Google Scholar
• NAKANISHI T, MIZUNO Y, GOTO I et al.: A nationwide collaborative study on the long-term effects of bromocriptine in patients with Parkinson's disease. The fourth interim report. Ear: Neurol. (1991) 31 (Suppl. 1):3–16.
   Google Scholar
• PRZUNTEK H, WELZEL D, BLUMNER E et al: Bromocriptine lessens the incidence of mortality in L-dopa-treated parkinsonian patients: prado-study discontinued (see comments). Ear: j Clin. Pharmacol. (1992) 43(0357–363.
   PubMedGoogle Scholar
• BAAS HK, SCHUELER P: Efficacy of cabergoline in long-term use: results of three observational studies in 1,500 patients with Parkinson's disease. Eur. Neurol. (2001) 46\(Suppl. 1):18–23.
   Google Scholar
• CLARKE CE, DEANE KD: Cabergoline versus bromocriptine for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst. Rev (2001) (1):CD001519.
   Google Scholar
• COLAO A, LOMBARDI G, ANNUNZIATO L: Cabergoline. Expert. Opin. Pharmacother. (2000) 1(3):555–574.
   PubMedGoogle Scholar
• ALLAIN H, DESTEE A, PETIT H et al.: Five-year follow-up of early lisuride and levodopa combination therapy versus levodopa monotherapy in de novo Parkinson's disease. The French Lisuride Study Group. Ear: Neurol. (2000) 44(1):22–30.
   PubMedGoogle Scholar
• CLARKE CE, SPELLER JM: Lisuride forlevodopa-induced complications in Parkinson's disease. Cochrane Database Syst. Rev (2000) (2):CD001515.
   Google Scholar
• GILLE G, RAUSCH WD, HUNG ST et al.: Protection of dopaminergic neurons in primary culture by lisuride." Neural Transm. (2002) 109(2):157–169.
   Google Scholar
• JANSEN PA, HERINGS RIVI, SAMSON MM et al.: Quick titration of pergolide in cotreatment with domperidone is safe and effective. Clin. Neuropharmacol (2001) 24(3):177–180.
   PubMedGoogle Scholar
• BONUCCELLI U, COLZI A, DEL DOTTO P: Pergolide in the treatment of patients with early and advanced Parkinson's disease. Gin. Neuropharmacol (2002) 25(1):1–10.
   PubMedGoogle Scholar
• DELEU D, NORTHWAY MG, HANSSENS Y: Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin. Pharmacokinet. (2002) 41(4):261–309.
   PubMed Web of Science ®Google Scholar
• HUBBLE JP: Long-term studies of dopamine agonists. Neurol (2002) 58(4 Suppl. 1):S42–S50.
   Google Scholar
• KAYE CM, NICHOLLS B: Clinical pharmacokinetics of ropinirole. Clin. Pharmacokinet. (2000) 39(4):243–254.
   PubMed Web of Science ®Google Scholar
• GIMENEZ-ROLDAN S, ESTEBAN EM, MATEO D: Switching from bromocriptine to ropinirole in patients with advanced Parkinson's disease: open label pilot responses to three different dose-ratios. Clin. Neuropharmacol (2001) 24(6):346–351.
   PubMedGoogle Scholar
• BRUNT ER, BROOKS DJ, KORCZYN AD, MONTASTRUC JL, STOCCHI F: A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa..1. Neural Transm. (2002) 109(4):489–502.
   Google Scholar
• HOMANN CN, WENZEL K, SUPPAN K et al.: Sleep attacks in patients taking dopamine agonists: review. Br. Med.' (2002) 324(7352):1483–1487.
   PubMedGoogle Scholar
• SCHRAG A, KEENS J, WARNER J: Ropinirole for the treatment of tremor in early Parkinson's disease. Eur: Neurol (2002) 9(3):253–257.
   Google Scholar
• BIGLAN KM, HOLLOWAY RG: A review of pramipexole and its clinical utility in Parkinson's disease. Expert. Opin. Pharmacother: (2002) 3(2):197–210.
   PubMedGoogle Scholar
• POGARELL 0, GASSER T, VAN HILTEN JJ et al.: Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study. Neura. Neurosurg. Psychiatry (2002) 72(6):713–720.
   Google Scholar
• GOETZ CG, BLASUCCI L, STEBBINS GT: Switching dopamine agonists in advanced Parkinson's disease: is rapid titration preferable to slow? Neurol (1999) 52(6):1227–1229.
   PubMed Web of Science ®Google Scholar
• GOETZ CG, TANNER CM, GLANTZ RH, KLAWANS HL: Chronic agonist therapy for Parkinson's disease: a 5-year study of bromocriptine and pergolide. Neurol (1985) 35(5):749–751.
   PubMedGoogle Scholar
• GOETZ CG, SHANNON KM, TANNER CM, CARROLL VS, KLAWANS HL: Agonist substitution in advanced Parkinson's disease. Neurol (1989) 39(8):1121–1122.
   PubMedGoogle Scholar
• HUTTON JT, METMAN LV, CHASE TN et al.: Transdermal dopaminergic D(2) receptor agonist therapy in Parkinson's disease with N-0923 TDS: a double-blind, placebo-controlled study. Mov. Disord. (2001) 16(3):459–463.
   PubMed Web of Science ®Google Scholar
• LEWITT PA: Clinical trials of neuroprotection in Parkinson's disease: long-term selegiline and a-tocopherol treatment. I Neural Transm. Stipp]. (1994) 43:171–181.
   PubMedGoogle Scholar
• PRZUNTEK H, CONRAD B, DICHGANS J et al.: A 5-year long-term trial on the effect of selegiline in early parkinsonian patients treated with levodopa. Eucf Neurol (1999) 6(2):141–150.
   PubMed Web of Science ®Google Scholar
• TOGGAS SM, MASLIAH E, MUCKE L: Prevention of HIV-1 gp120-induced neuronal damage in the central nervous system of transgenic mice by the NMDA receptor antagonist memantine. Brain Res. (1996) 706(2):303–307.
   PubMed Web of Science ®Google Scholar
• BURSTEIN ME, SERBIN AV, KHAKHULINA TV et al.: Inhibition of HIV-1 replication by newly developed adamantane- containing polyanionic agents. Antiviral Res. (1999) 41(3):135–144.
   PubMed Web of Science ®Google Scholar
• NATH A, HAUGHEY NJ, JONES M, ANDERSON C, BELL JE, GEIGER JD: Synergistic neurotoxicity by human immunodeficiency virus proteins Tat and gp120: protection by memantine. Ann. Neurol (2000) 47(2):186–194.
   PubMed Web of Science ®Google Scholar
• UITTI RJ, RAJPUT AH, AHLSKOG JE et al.: Amantadine treatment is an independent predictor of improved survival in Parkinson's disease. Neurol (1996) 46(6):1551–1556.
   PubMedGoogle Scholar
• OLANOW CW, MYLLYLA VV, SOTANIEMI KA et al.: Effect of selegiline on mortality in patients with Parkinson's disease: a meta-analysis. Neurol (1998) 51(3):825–830.
   PubMedGoogle Scholar
• DEIGNER HP, HABERKORN U, KINSCHERF R: Apoptosis modulators in the therapy of neurodegenerative diseases. Expert. Opin. Investig. Drugs (2000) 9(4):747–764.
   PubMed Web of Science ®Google Scholar
• HIRSCH EC, HUNOT S, FAUCHEUX B, et al: Dopaminergic neurons degenerate by apoptosis in Parkinson's disease. Mov. Disord. (1999) 14(2):383–385.
   PubMedGoogle Scholar
• OLANOW CW, TATTON WG: Etiology and pathogenesis of Parkinson's disease. Ann. Rev Neurosci (1999) 22:123–144.
   PubMed Web of Science ®Google Scholar
• INNIS RB, MAREK KL, SHEFF K et al.: Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with (123I)13-CIT. Mov. Disord. (1999) 14(3):436–442.
   PubMedGoogle Scholar
• SEIBYL JP, MAREK K, SHEFF K et al: Test/retest reproducibility of iodine-123-0-CIT SPECT brain measurement of dopamine transporters in Parkinson's patients. Nucl. Med. (1997) 38(9):1453–1459.
   Google Scholar
• AHLSKOG JE, UITTI RJ, O'CONNOR MK et al.: The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease. Mov. Disord. (1999) 14(6)940–946.
   Google Scholar
• EKESBO A, RYDIN E, TORSTENSON R, SYDOW 0, LAENGSTROM B, TEDROFF J: Dopamine autoreceptor function is lost in advanced Parkinson's disease. Neurol (1999) 52(1):120–125.
   PubMed Web of Science ®Google Scholar
• BLUM-DEGEN D, MOLLER T, KUHN W, GERLACH M, PRZUNTEK H, RIEDERER P: Interleukin-113 and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci. Lett. (1995) 202(1-2):17–20.
   PubMed Web of Science ®Google Scholar
• MOGI M, HARADA M, NARABAYASHI H, INAGAKI H, MINAMI M, NAGATSU T: Interleuldn (IL)-1 13, IL-2, IL-4, IL-6 and transforming growth factor-a levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. Neurosci. Lett. (1996) 211(1):13–16.
   PubMed Web of Science ®Google Scholar
• MCGEER PL, MCGEER EG: Glial cell reactions in neurodegenerative diseases: pathophysiology and therapeutic interventions. Alzheimer Dis. Assoc. Disord (1998) 12 (Suppl. 2):S1–S6.
   Google Scholar
• MOGI M, NAGATSU T: Neurotrophins and cytokines in Parkinson's disease. Adv. Neural (1999) 80:135–139.
   PubMedGoogle Scholar
• MASTRONARDI CA, YU WH, MCCANN S: Lipopolysaccharide-induced tumor necrosis factor-a release is controlled by the central nervous system. Neureimmunemedulation (2001) 9(3):148–156.
   PubMed Web of Science ®Google Scholar
• SHAUNAK S, WILKINS A, PILLING JB, DICK DJ: Pericardial, retroperitoneal, and pleural fibrosis induced by pergolide. Neura Neuresurg. Psychiatry (1999) 66(1):79–81.
   PubMed Web of Science ®Google Scholar
• IVERSEN BM, JOHANNESEN JW, NORDAHL E, OFSTAD J, THUNOLD S, WILLASSEN Y: Retroperitoneal fibrosis during treatment with methydopa. Lancet (1975) 2(7929):302–304.
   PubMedGoogle Scholar
• CLARKE CE: Medical management of Parkinson's disease.' Neurel Neuraturg. Psychiatry (2002) 72\(Suppl. 1):122–I27.
   Google Scholar
• PRZUNTEK H, BITTKAU S, BLIESATH H et al.: Budipine provides additional benefit in patients with Parkinson's disease receiving a stable optimum dopaminergic drug regimen. Arch. Neural. (2002) 59(5):803–806.
   PubMedGoogle Scholar